NEW ORLEANS--(BUSINESS WIRE)--New data presented at the American Diabetes Association (ADA) 69th Annual Scientific Sessions showed that initial treatment with JANUMET™ (sitagliptin/metformin) provided greater blood sugar improvements in drug-naïve patients with type 2 diabetes, compared with metformin alone. In separate post-hoc analyses, data pooled from studies of 104 weeks in duration showed JANUVIA™ (sitagliptin), when taken alone (two studies) or in combination with metformin (two studies), provided significant blood sugar lowering, which was sustained over two years.
